ORCA
Online Research @ Cardiff

Clear Cookie - decide language by browser settings

Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2

Zhou, You

, Llauradó, Gemma, Oresic, Matej, Hyötyläinen, Tuulia, Orho-Melander, Marju and Yki-Järvinen, Hannele 2015. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. Journal of Hepatology 62 (3) , pp. 657-663. 10.1016/j.jhep.2014.10.010

Preview	PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (442kB) \| Preview
Preview	PDF - Supplemental Material Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (194kB) \| Preview

Official URL: http://dx.doi.org/10.1016/j.jhep.2014.10.010

Abstract

Background & Aims The Glu167Lys (E167K) variant in the transmembrane 6 superfamily member 2 protein (TM6SF2) was recently shown to influence liver fat (LFAT) content. We aimed at studying how this variant influences circulating triacylglycerol (TAG) signatures and whether it influences hepatic or adipose tissue insulin sensitivity. Methods We genotyped 300 Finnish subjects for the E167K (rs58542926) variant in TM6SF2 and for the I148M (rs738409) variant in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) in whom LFAT was measured using 1H-MRS and circulating lipids by UPLC-MS. We compared the plasma lipidome between E167K carriers (TM6SF2EK/KK) and non-carriers (TM6SF2EE), and between three groups of NAFLD: (i) carriers of the E167K but not of the I148M variant in PNPLA3 (‘TM6SF2 NAFLD’), (ii) carriers of the I148M but not of the E167K variant (‘PNPLA3 NAFLD’), and (iii) non-carriers of either risk allele (‘Non-risk NAFLD’). Hepatic and adipose tissue insulin sensitivities were measured using the euglycemic hyperinsulinemic clamp technique combined with infusion of [3-3H]glucose in 111 subjects. Results The LFAT content was 34% higher in the TM6SF2EK/KK (13.07 ± 1.57%) than in the TM6SF2EE group (9.77 ± 0.58%, p = 0.013). The effect of insulin on glucose production and lipolysis were significantly higher in the TM6SF2EK/KK than in the TM6SF2EE group. Comparison of the three NAFLD groups with similar LFATs showed that both the ‘TM6SF2 NAFLD’ and ‘PNPLA3 NAFLD’ had significantly lower triglyceride levels and were characterized by lower levels of most common TAGs compared to the ‘Non-risk NAFLD’ group. Conclusions We conclude that the E167K variant in TM6SF2 is associated with a distinct subtype of NAFLD, characterized by preserved insulin sensitivity with regard to lipolysis, hepatic glucose production and lack of hypertriglyceridemia despite a clearly increased LFAT content.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Publisher:	Elsevier
ISSN:	0168-8278
Date of First Compliant Deposit:	7 November 2017
Date of Acceptance:	6 October 2014
Last Modified:	07 Nov 2024 00:30
URI:	https://orca.cardiff.ac.uk/id/eprint/89723